## **Special Issue**

# COVID-19 Medicines in Pharmacogenomics

## Message from the Guest Editors

Pharmacogenomics has begun to move to the center stage of COVID-19 drug design and development, including repurposed drugs and different vaccine platforms that are being used for COVID-19. Predefined drug (i.e., authorized for emergency use) safety and efficacy can be detected more effectively through pharmacogenomics during and after clinical trials.

This Special Issue invites potential manuscripts that cover topics including pharmacogenomics, biomarkers, drug repurposing, drug–target interactions, drug–gene interactions, and advances in artificial intelligence in pharmacogenomics related to COVID-19 and coronavirus–mediated disease.

### **Guest Editors**

Dr. Satyavani Kaliamurthi

Centre for Research in Molecular Modeling (CERMM), Concordia University, Montreal, QC H4B1R6, Canada

Dr. Gurudeeban Selvarai

Centre for Research in Molecular Modeling (CERMM), Concordia University, Montreal, QC H4B1R6, Canada

### Deadline for manuscript submissions

closed (20 February 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



### mdpi.com/si/135266

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpl.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

